Institution
University of North Carolina at Chapel Hill
Education•Chapel Hill, North Carolina, United States•
About: University of North Carolina at Chapel Hill is a education organization based out in Chapel Hill, North Carolina, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 81393 authors who have published 185327 publications receiving 9948508 citations. The organization is also known as: University of North Carolina & North Carolina.
Topics: Population, Poison control, Health care, Cancer, Medicine
Papers published on a yearly basis
Papers
More filters
Loyola University Chicago1, Radiation Therapy Oncology Group2, Memorial Sloan Kettering Cancer Center3, Wayne State University4, University of Toronto5, Tom Baker Cancer Centre6, University of Rochester7, University of Arizona8, University of North Carolina at Chapel Hill9, University of California, Davis10, NorthShore University HealthSystem11, University Health Network12, Vanderbilt University13, Medical University of South Carolina14, Mayo Clinic15, Primary Children's Hospital16, University of Texas MD Anderson Cancer Center17
TL;DR: The primary endpoint was overall survival (OS) and an exploratory analysis, OS was improved for patients who underwent lobectomy, but not pneumonectomy, versus chemotherapy plus radiotherapy, compared with standard concurrent chemotherapy and definitive radiotherapy without resection.
1,202 citations
Fred Hutchinson Cancer Research Center1, University of Washington2, American Society of Clinical Oncology3, Cleveland Clinic4, University of British Columbia5, Pennsylvania State University6, Duke University7, Emory University8, University of Rochester9, University of North Carolina at Chapel Hill10, McMaster University11, University of Southern California12, University of California, San Francisco13, University of Michigan14
TL;DR: Current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer and oncology professionals should educate patients about the signs and symptoms of VTE.
Abstract: Purpose To provide current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.
1,201 citations
TL;DR: It is demonstrated that selective clearance of SCs by a pharmacological agent is beneficial in part through its rejuvenation of aged tissue stem cells, demonstrating that senolytic drugs may represent a new class of radiation mitigators and anti-aging agents.
Abstract: Senescent cells (SCs) accumulate with age and after genotoxic stress, such as total-body irradiation (TBI). Clearance of SCs in a progeroid mouse model using a transgenic approach delays several age-associated disorders, suggesting that SCs play a causative role in certain age-related pathologies. Thus, a 'senolytic' pharmacological agent that can selectively kill SCs holds promise for rejuvenating tissue stem cells and extending health span. To test this idea, we screened a collection of compounds and identified ABT263 (a specific inhibitor of the anti-apoptotic proteins BCL-2 and BCL-xL) as a potent senolytic drug. We show that ABT263 selectively kills SCs in culture in a cell type- and species-independent manner by inducing apoptosis. Oral administration of ABT263 to either sublethally irradiated or normally aged mice effectively depleted SCs, including senescent bone marrow hematopoietic stem cells (HSCs) and senescent muscle stem cells (MuSCs). Notably, this depletion mitigated TBI-induced premature aging of the hematopoietic system and rejuvenated the aged HSCs and MuSCs in normally aged mice. Our results demonstrate that selective clearance of SCs by a pharmacological agent is beneficial in part through its rejuvenation of aged tissue stem cells. Thus, senolytic drugs may represent a new class of radiation mitigators and anti-aging agents.
1,200 citations
TL;DR: It is found that an AAV vector containing the LacZ gene resulted in expression of β-galactosidase up to three months post-injection in vivo, and safe and stable TH gene transfer into the denervated striatum may have potential for the genetic therapy of Parkinson's disease.
Abstract: Adeno-associated viral (AAV) vectors are non-pathogenic, integrating DNA vectors in which all viral genes are removed and helper virus is completely eliminated. To evaluate this system in the post-mitotic cells of the brain, we found that an AAV vector containing the lacZ gene (AAVlac) resulted in expression of beta-galactosidase up to three months post-injection in vivo. A second vector expressing human tyrosine hydroxylase (AAVth) was injected into the denervated striatum of unilateral 6-hydroxydopamine-lesioned rats. Tyrosine hydroxylase (TH) immunoreactivity was detectable in striatal neurons and glia for up to four months and we also found significant behavioural recovery in lesioned rats treated with AAVth versus AAVlac controls. Safe and stable TH gene transfer into the denervated striatum may have potential for the genetic therapy of Parkinson's disease.
1,199 citations
TL;DR: ExoCAT provided significant neuroprotective effects in in vitro and in vivo models of PD and has a potential to be a versatile strategy to treat inflammatory and neurodegenerative disorders.
1,197 citations
Authors
Showing all 82249 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Walter C. Willett | 334 | 2399 | 413322 |
| Salim Yusuf | 231 | 1439 | 252912 |
| David J. Hunter | 213 | 1836 | 207050 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Eric J. Topol | 193 | 1373 | 151025 |
| Dennis W. Dickson | 191 | 1243 | 148488 |
| Scott M. Grundy | 187 | 841 | 231821 |
| Peidong Yang | 183 | 562 | 144351 |
| Patrick O. Brown | 183 | 755 | 200985 |
| Eric Boerwinkle | 183 | 1321 | 170971 |
| Alan C. Evans | 183 | 866 | 134642 |
| Anil K. Jain | 183 | 1016 | 192151 |
| Terrie E. Moffitt | 182 | 594 | 150609 |
| Aaron R. Folsom | 181 | 1118 | 134044 |
| Valentin Fuster | 179 | 1462 | 185164 |